Psoriasis patients switch biologics in new Real-World study
NCT ID NCT07449234
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This study watches 200 adults with moderate to severe psoriasis who switch from ustekinumab to guselkumab in everyday medical practice. Researchers track how well the new drug clears skin symptoms and check for side effects over 52 weeks. The goal is to see if guselkumab works safely after switching from another biologic.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
LKH-Univ. Klinikum Graz
Graz, 8036, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis